Date: 2012-03-29
Type of information:
phase:
Announcement: initiation of a proof-of-concept study
Company: PharmaNeuroBoost (Belgium)
Product: PNB02
Action mechanism: PNB02 is the fixed dose combination of low dose risperidone and low dose pipamperone. Risperidone is a well-established ‘atypical’ antipsychotic and pipamperone is a well established mild neuroleptic agent that has been used extensively in some European countries for many years and is a New Drug Entity in the USA. The PNB02 concept has been granted with broad IP coverage.
Disease: schizophrenia
Therapeutic area: CNS diseases - Mental diseases
Country: Belgium
Trial details:
Latest
news: PharmaNeuroBoost has obtained approval from the Belgian Authorities and from the Central Ethics Committee to initiate a Proof-of-Concept study in patients with chronic schizophrenia. The objectives
of this study are to evaluate the effect of PNB02, PNB’s second product in development, on functional Magnetic Resonance Imaging (MRI) of the brain and to evaluate the clinical effect of PNB02 treatment in patients with chronic schizophrenia who are suffering from residual symptoms.
